Mon-Fri 9:00-18:00 CET+39 095 7211344info@vitasanlabs.com

Family · Pharmaceutical analytical standards

Nevirapine

The first non-nucleoside reverse transcriptase inhibitor, approved in 1996 against HIV-1: it binds directly to the virus's enzyme, blocking it, and in treatment it is used in combination with other antiretrovirals. This family brings together the active ingredient, pharmacopoeial impurities, labelled standards and other impurities.

Did you know?A study carried out in Uganda and published in 1999 showed that a very simple treatment, given to the mother during labour and to the newborn, greatly reduced mother-to-child transmission of HIV.

NevirapineGo to the active ingredient →
NevirapineActive ingredientNevirapineCat. No. P-N043-001CAS 129618-40-2
Nevirapine-d4Isotopically labelledNevirapine-d4Cat. No. P-N043-006CAS 1051418-95-1
Nevirapine-d5Isotopically labelledNevirapine-d5Cat. No. P-N043-007CAS 1189717-29-0

EDQM standards 3

The official European Pharmacopoeia standards for this family.

Need a molecule you cannot find?

Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.